| Assessment Status | Rapid Review Complete |
| HTA ID | 24047 |
| Drug | Eplontersen |
| Brand | Wainzua® |
| Indication | Eplontersen (Wainzua®) is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy. |
| Assessment Process | |
| Rapid review commissioned | 15/11/2024 |
| Rapid review completed | 19/12/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that eplontersen not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
